GlassScriptPhysician profile
Jennifer E O'Sullivan
NPI 1497492326
$1,465.79
in general payments reported to CMS, 2019-2025
29 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $391 · 2024: $416 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.59 | 2023-2025 | |
| Madrigal Pharmaceuticals | $166.59 | 2025 | Rezdiffra |
| Novo Nordisk INC | $127.63 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $96.84 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ferring Pharmaceuticals INC. | $83.06 | 2022-2024 | Rebyota |
| Astellas Pharma US INC | $60.66 | 2023 | Veozah |
| Lilly USA, LLC | $60.11 | 2022-2023 | Mounjaro |
| Gilead Sciences, INC. | $59.32 | 2024 | |
| Exact Sciences Corporation | $58.83 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $55.83 | 2022-2025 | |
| Viiv Healthcare Company | $44.65 | 2022-2023 | Rukobia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.66 | 2023-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.26 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.60 | 2023 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $30.83 | 2024-2025 | Otezla, Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $29.53 | 2024 | Trogarzo, Egrifta |
| Indivior INC. | $27.27 | 2024 | Sublocade |
| Csl Behring | $23.80 | 2023 | Hizentra |
| Corium, LLC | $21.51 | 2025 | Azstarys |
| Insmed, INC. | $20.39 | 2022 | |
| Pfizer INC. | $18.18 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.48 | 2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $16.20 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.01 | 2024 | Belbuca |
| Takeda Pharmaceuticals U.S.A., INC. | $14.22 | 2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2025 | |
| Inogen, INC. | $8.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer O'Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.